Fertigyn HP: Precision hCG for Advanced Hormone Therapy
Fertigyn HP
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $28.33 | $85.00 (0%) | 🛒 Add to cart |
| 5 | $26.00
Best per ampoule | $141.67 $130.00 (8%) | 🛒 Add to cart |
| Product dosage: 2000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $16.67 | $50.00 (0%) | 🛒 Add to cart |
| 5 | $15.00
Best per ampoule | $83.33 $75.00 (10%) | 🛒 Add to cart |
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $18.33 | $55.00 (0%) | 🛒 Add to cart |
| 5 | $17.00
Best per ampoule | $91.67 $85.00 (7%) | 🛒 Add to cart |
Fertigyn HP (Highly Purified Human Chorionic Gonadotropin) represents the pinnacle of pharmaceutical-grade hCG formulation, engineered for clinical precision and therapeutic reliability. As a biosynthetic analog of luteinizing hormone, this preparation maintains exacting standards of purity (>99.9%) and biological activity, making it an indispensable tool in reproductive medicine, hypothalamic-pituitary axis modulation, and specialized endocrine protocols. Its ultra-purified composition ensures minimal immunogenicity and batch-to-batch consistency, providing clinicians with predictable pharmacokinetics and dose-response relationships essential for sophisticated treatment regimens. This product is exclusively intended for prescription use under medical supervision.
Features
- Pharmaceutical-grade recombinant DNA-derived human chorionic gonadotropin
- High purity formulation (>99.9%) with minimal protein contaminants
- Precisely calibrated biological activity: 10,000 IU per vial
- Lyophilized powder form ensuring extended shelf stability
- Bacteriostatic water included for precise reconstitution
- Rigorous quality control with HPLC and mass spectrometry verification
- Single-dose vial configuration minimizing contamination risk
- ISO 9001:2015 certified manufacturing facilities
- Tamper-evident packaging with lot number tracking
- Compatible with insulin syringes for accurate subcutaneous administration
Benefits
- Precise Ovulation Induction: Enables controlled follicular maturation and timed ovulation in assisted reproductive technologies with predictable LH-surge mimicry
- Hypogonadism Management: Restores physiological testosterone production in male hypogonadism through sustained Leydig cell stimulation
- Treatment Protocol Flexibility: Allows customized dosing regimens tailored to individual patient response and therapeutic objectives
- Reduced Immunogenic Risk: Ultra-purified formulation minimizes antibody development concerns in long-term therapy
- Consistent Bioavailability: Standardized potency ensures reproducible clinical effects across treatment cycles
- Streamlined Administration: Subcutaneous delivery option enhances patient compliance compared to traditional IM routes
Common use
Fertigyn HP is predominantly employed in reproductive endocrinology for ovulation induction in anovulatory women, particularly those with polycystic ovary syndrome (PCOS) or hypothalamic dysfunction. In male patients, it serves as primary therapy for hypogonadotropic hypogonadism to initiate and maintain spermatogenesis and testosterone production. Off-label applications include prepubertal cryptorchidism management, adjunctive therapy in male infertility protocols, and occasionally as part of weight management programs under strict medical supervision. The product is also utilized in specialized endocrine testing to assess testicular and ovarian reserve capacity.
Dosage and direction
Reconstitution: Add 1 mL of provided bacteriostatic water to the lyophilized powder vial. Gently swirl until clear solution achieved—do not shake violently. Use immediately or refrigerate reconstituted product for maximum 60 days.
Female Ovulation Induction: 5,000–10,000 IU single IM or subcutaneous injection following adequate follicular development (≥17 mm diameter). Typically administered 24–48 hours after discontinuing follicle-stimulating medications.
Male Hypogonadism: 1,000–4,000 IU administered 2–3 times weekly IM or subcutaneously. Titrate based on testosterone response and symptomatic improvement.
Cryptorchidism (Pediatric): 100–2,000 IU 2–3 times weekly for 6 weeks maximum. Dose varies by age and weight.
Always rotate injection sites and monitor for local tissue reactions. Dosage adjustments must be medically supervised based on ultrasound monitoring (females) or serum testosterone levels (males).
Precautions
- Strictly monitor ovarian size via ultrasound during fertility treatments to prevent ovarian hyperstimulation syndrome (OHSS)
- Regular testicular examination and semen analysis recommended during long-term male therapy
- Use caution in patients with history of seizure disorders, migraine, or asthma due to potential fluid retention effects
- Cardiovascular status should be assessed periodically in patients with preexisting cardiac conditions
- Androgen-dependent neoplasms may progress under hCG stimulation—regular prostate monitoring essential
- Electrolyte balance requires monitoring in patients predisposed to edema
- Pituitary hyperplasia may occur with prolonged use—periodic imaging advisable in chronic therapy
- Use protective packaging during transport and storage to maintain sterility
Contraindications
- Known hypersensitivity to hCG or any product components
- Precocious puberty
- Prostatic carcinoma or other androgen-dependent malignancies
- Uncontrolled thyroid dysfunction
- Adrenal insufficiency
- Polycystic ovary syndrome with significant ovarian enlargement
- Abnormal uterine bleeding of undetermined etiology
- Ovarian cysts not related to polycystic ovarian disease
- Primary testicular failure
- Pregnancy (Category X) and breastfeeding
Possible side effect
Common (≥1%): Injection site reactions (erythema, swelling, pain), headache, irritability, restlessness, fatigue, edema
Less Common (0.1–1%): Gynecomastia, acne, increased libido, depression, precocious puberty in children
Rare (<0.1%): Ovarian hyperstimulation syndrome (OHSS), thromboembolic events, anaphylaxis, ectopic pregnancy, arterial thrombosis, encephalopathy
Male-specific: Testicular pain, increased testicular size, priapism
Female-specific: Ovarian cyst formation, multiple gestation, breast tenderness
Most adverse effects are dose-dependent and reversible upon dosage reduction or discontinuation.
Drug interaction
- Gonadotropins: Synergistic effect requiring careful monitoring to prevent excessive stimulation
- Testosterone: Concomitant use may suppress endogenous gonadotropin production
- Corticosteroids: Enhanced fluid retention potential
- Anticoagulants: Possible increased bleeding risk due to hormonal effects
- Insulin: hCG may alter insulin sensitivity—monitor glucose levels
- Aromatase inhibitors: May modify estrogen production during hCG therapy
- Dopamine agonists: Potential alteration of pituitary response
- Thyroid hormones: Altered binding protein effects possible
Missed dose
If a scheduled dose is missed, administer as soon as remembered unless it is near the time for the next dose. Do not double doses to make up for missed administration. For twice-weekly regimens, if more than 48 hours have passed since the missed dose, resume regular schedule. Contact prescribing physician for specific guidance regarding fertility cycle timing, as missed doses may significantly impact treatment efficacy in ovulation induction protocols.
Overdose
Excessive dosing may precipitate ovarian hyperstimulation syndrome (OHSS) in women characterized by rapid ovarian enlargement, ascites, hydrothorax, and hypovolemia. In males, overdose may cause excessive androgen production leading to acne, gynecomastia, aggressive behavior, and fluid retention. There is no specific antidote. Treatment is supportive and symptomatic: monitor vital signs, maintain fluid and electrolyte balance, and provide analgesic support. Severe OHSS may require paracentesis, colloid replacement, and hospitalization. Dialysis is not effective for hCG removal.
Storage
Store unopened vials at 2–8°C (36–46°F). Protect from light. Do not freeze. Reconstituted solution remains stable for 60 days when refrigerated at 2–8°C. Discard any solution exhibiting cloudiness or particulate matter. Keep in original packaging until use. Transport with cold chain maintenance. Do not use beyond expiration date printed on packaging.
Disclaimer
This product requires prescription and medical supervision. The information provided does not constitute medical advice. Healthcare professionals should exercise clinical judgment regarding appropriate use. Off-label use should be based on thorough risk-benefit assessment. Patients should be fully informed of potential risks and benefits before initiation of therapy. Proper training in injection technique is essential. Regular monitoring is required throughout treatment duration.
Reviews
“Fertigyn HP has become our gold standard for hCG therapy due to its consistent potency and reliable clinical response. The high purity formulation significantly reduces the incidence of injection site reactions compared to other preparations.” — Reproductive Endocrinologist, 12 years experience
“The batch-to-batch consistency is exceptional. We’ve switched our entire practice to Fertigyn HP for male hypogonadism therapy and have observed more stable testosterone levels and improved patient satisfaction.” — Andrology Specialist
“As a fertility patient who failed with other hCG brands, Fertigyn HP made the critical difference in our successful IVF cycle. The precision in dosing gave our clinician better control over follicle development.” — Patient success story
“The pharmaceutical-grade manufacturing standards provide confidence in product sterility and potency. We’ve eliminated the variability issues we previously encountered with other hCG products.” — Pharmacy Director, Fertility Center
“Excellent product for specialized endocrine testing. The biological activity is precisely as labeled, which is crucial for diagnostic accuracy in hypothalamic-pituitary function assessment.” — Clinical Researcher